Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

At a median follow-up of 17 months, median PFS was estimated at beyond 19.3 months, with a 6-month PFS ... as well as by downstream signaling." Thus, the researchers hypothesized adding PI3K ...

Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifu ...

Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...

Pfizer is wrapping up its lucrative goodbye to Haleon, raising approximately $3.3 billion by offloading its remaining 7.3% ...

IL-33 has increasingly been shown as a key regulator of type 2 inflammation via signaling through its receptor ... 10 ng/mL IL-6, 25 ng/mL IL-3, and 10 ng/mL GM-CSF (PeproTech). The media was ...

The stock of GlaxoSmithKline Pharmaceuticals (GSK Pharma) hit a three-month high of ₹2,640 a share as it surged 5 per cent on Monday before closing at ₹2,638. During the past seven trading days, the ...

In work conducted by Jining Medical University investigators, synthesis and optimization of a previously reported ...

Discover GSK's impressive stock surge, boosted by strong earnings, a share buyback program, and a focus on specialty medicines.

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...